Even as the diagnostics industry continues to pursue more sophisticated approaches to cancer testing, a group from the U.K. has come up with a simple blood test that could generate much more bang for the buck.
Roche's Ventana Medical Systems will develop a companion diagnostic test with Germany's Merck KGaA that can be used for many different cancer types.
Asuragen gained approval to start offering two of its key molecular diagnostic tests in New York state, milestones that will help boost the standard of care and give the Texas company another opportunity to grow its market reach.
When Dendreon was trying to bring its cancer vaccine Provenge to market, many doubted whether it could overcome the associated manufacturing and logistical hurdles. Ultimately Dendreon did better than some expected, but not as well as it hoped. And the same problems that made the cost of producing and shipping Provenge a burden for Dendreon still hang over the sector.
Researchers have discovered that, when triggered, certain chemical signals can cause cells to transform into an invasive, liquidy state, giving them the ability to navigate freely through the body. The findings could help drug developers produce new techniques to halt the spread of cancer cells and prevent secondary tumors.
Researchers in California believe they've zeroed in on biomarkers--microRNAs--that will help determine who will respond best to the treatment and help boost its success rate.
Germany's Definiens has raised €15 million ($20.4 million) in new financing to expand into digital tissue diagnostics, planning to use Big Data and image analysis to spot cancers.
After finding success using its technology to screen unborn babies for chromosomal problems, Natera is looking to see how well its diagnostic platform can detect and monitor cancer.
UCA spinoff ImaginAb and Duke-NUS Graduate Medical School Singapore will team up to develop in vivo molecular imaging agents focused on cancer, immunology and disease areas unique to Asia.
Roche's Ventana Medical Systems and MedImmune said they will jointly develop an assay to help test a MedImmune immunotherapy for non-small cell lung cancer.